KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Paul K. Audhya Sells 2,187 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul K. Audhya sold 2,187 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $9.87, for a total value of $21,585.69. Following the completion of the transaction, the insider now owns 97,012 shares of the company’s stock, valued at approximately $957,508.44. The trade was a 2.20 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

KalVista Pharmaceuticals Stock Up 1.1 %

KalVista Pharmaceuticals stock traded up $0.11 during midday trading on Wednesday, reaching $10.09. 162,899 shares of the stock traded hands, compared to its average volume of 483,293. The stock has a market cap of $436.09 million, a P/E ratio of -2.83 and a beta of 0.92. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.39 and a 12 month high of $16.88. The stock’s fifty day moving average is $10.99 and its 200-day moving average is $11.94.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($0.91) by $0.04. On average, equities analysts predict that KalVista Pharmaceuticals, Inc. will post -2.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

KALV has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Monday, October 7th. Needham & Company LLC reiterated a “buy” rating and set a $32.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, September 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, September 9th.

Institutional Trading of KalVista Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. PEAK6 Investments LLC acquired a new position in shares of KalVista Pharmaceuticals in the 1st quarter valued at about $178,000. Price T Rowe Associates Inc. MD increased its position in shares of KalVista Pharmaceuticals by 4.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company’s stock valued at $263,000 after acquiring an additional 944 shares during the last quarter. Zimmer Partners LP acquired a new position in KalVista Pharmaceuticals in the 1st quarter valued at about $830,000. Rosalind Advisors Inc. increased its stake in KalVista Pharmaceuticals by 17.4% during the 2nd quarter. Rosalind Advisors Inc. now owns 337,985 shares of the specialty pharmaceutical company’s stock worth $3,981,000 after buying an additional 50,000 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of KalVista Pharmaceuticals by 21.0% in the second quarter. Bank of New York Mellon Corp now owns 135,600 shares of the specialty pharmaceutical company’s stock valued at $1,597,000 after acquiring an additional 23,547 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).